Glyxambi

One of the top 20 pharmaceutical companies in the world, Boehringer Ingelheim is leader in the production of the highest technical and scientific quality specialty pharmaceuticals.

CH+B was retained on the occasion of the launch of a new product -- Glyxambi, a type 2 diabetes drug.

"Past, present and future - we keep on innovating in healthcare" was our starting point.

The formal vocabulary is supported by two pillars. The first one shows an interaction among diabetes milestones, with significant and influential individuals who participated in the history of medicine and, most specifically, diabetes.

The second concept that supports design is the technology embedded in the product, which is consistently reflected in all formats. Physicians' conferences consisted of hologram projections and high visual impact videos.